Bristol cuts its BCMA losses
Meanwhile, the RayzeBio-originated RYZ101 is back in Action.
Roche’s Skyscraper looks on shaky foundations
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.
Apollomics shifts to a smaller niche
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.
The month ahead: July’s upcoming events
Earnings season begins again, while big readouts loom for ALX and Fibrogen.
EHA 2024 – J&J bows out as Roche looks to confirm
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.
Bayer changes tack in targeted lung cancer
As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.
ASCO 2024 – J&J shifts to a new radiopharma dosing strategy
The group is keeping faith with the novel target KLK2.
ASCO 2024 – Laura’s crossover conundrum
Tagrisso is a knockout on PFS, but only OS will show whether it should be given before patients progress.
